Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Study of safety and efficacy of commercial BCMA CAR T in systemic AL amyloidosis w/ myeloma finds ORR by AL criteria was 93% (5 VGPRs, 20 CRs; ide-cel ORR was 75% and 100% for cilta-cel); 12 and 18-mo OS rates were 85% and 81%.”
Title: The Safety and Efficacy of Commercial BCMA-Directed CAR T-Cell Therapy in Systemic AL Amyloidosis With Concurrent Myeloma
Authors: Matthew J. Rees, Raffaella Cassano Cassano, Melinda Tan, Eli Zolotov, Surbhi Sidana, Danai Dima, Jeries Kort, Aimaz Afrough, Mahmoud Gaballa, Oren Pasvolsky, Lekha Mikkilineni, Jack Khouri, Shahzad Raza, Saurabh S. Zanwar, Christopher J. Ferreri, Shaji Kumar, Adeel M. Khan, Shebli Atrash, Andrew J. Portuguese, Masooma Shifa Rana, Rahul Banerjee, Ciara Freeman, Brandon Blue, Krina K. Patel, Larry D. Anderson Jr, Omar Castaneda Puglianini, Leyla O. Shune, Noa Biran, Doris K. Hansen, Yi Lin
You can read the Full Article in American Journal of Hematology.
You can find more posts featuring Robert Orlowski on OncoDaily.
